Evaluating CTX112 for treating refractory autoimmune diseases in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label, multicenter Phase 1 study assessing the safety and preliminary efficacy of CTX112, a CAR T cell immunotherapy, in adults with refractory autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, and idiopathic inflammatory myopathy. The study aims to enroll up to 80 subjects who will receive genetically modified T cells derived from healthy donors, utilizing CRISPR-Cas9 technology for treatment. Participants will be monitored for safety and effectiveness throughout the study.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Age ≥18 years and \< 70 years of age.
2. Subjects must voluntarily sign a written informed consent and be willing and able to comply with all study requirements.
3. Adequate hematologic, renal, liver, cardiac and pulmonary organ function.
4. Subjects must agree to use acceptable methods of contraception.
5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.
6. Diagnosis of systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM).

For systemic lupus erythematosus (SLE) subjects:

\- Diagnosis of SLE by a board-certified rheumatologist that conforms with 2019 ACR/EULAR criteria. For lupus nephritis subjects, active, biopsy-proven proliferative lupus nephritis Class III or IV, either with or without the presence of Class V, and appropriate National Institutes of Health index activity score using the 2018 International Society of Nephrology/Renal Pathology Society criteria.

For Systemic Sclerosis (SSc) subjects:

\- Diagnosis of diffuse cutaneous systemic sclerosis (dcSSC) or SSc-ILD that conforms with 2013 ACR/EULAR criteria. Subjects should meet active skin or lung disease criteria.

For Idiopathic Inflammatory Myopathy (IIM) subjects:

\- Diagnosis with dermatomyositis (DM), polymyositis (PM) or myositis as part of rheumatologic overlap syndrome, antisynthetase (ASyS), or immune-mediated necrotizing myopathy (IMNM) that conforms with 2017 ACR/EULAR criteria for inflammatory myopathies. Subjects must meet moderate severe, skin, or lung involvement criteria.

Key Exclusion Criteria:

1. Prior anti-CD19 therapy or any gene therapy/genetically modified cell therapy.
2. Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.
3. Severe active or history of central nervous (CNS) involvement.
4. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement other than SLE, SSc or IIM.
5. Mixed connective tissue disease with no clear predominant disease.
6. Presence of study disease manifestations or other conditions that are likely to pose increase safety risks and/or confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.
7. History of primary or secondary immunodeficiency.
8. Presence or history of certain bacterial, viral or fungal infection.
9. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).
10. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.
11. History or current diagnosis of catastrophic anti-phospholipid syndrome or anti phospholipid syndrome that requires ongoing anticoagulation.
12. Pregnant or lactating.
13. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.

Where it's running

• UC San Diego Health
  La Jolla, California, United States Recruiting
• Stanford University Medical Center
  Redwood City, California, United States Recruiting
• Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center
  Chicago, Illinois, United States Recruiting
• University of Iowa
  Iowa City, Iowa, United States Recruiting
• Tulane University Medical Center
  New Orleans, Louisiana, United States Recruiting
• Boston Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Clinical Trials
• Email: medicalaffairs@crisprtx.com
• Phone: 1 877-214-4634

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zamtocabtagene Autologous CAR-T for Autoimmune Diseases

  This early-phase study tests whether a patient’s own CAR-T cells (zamto-cel) can be safely given after standard therapy to people with lupus or systemic sclerosis.

  Recruiting Phase 1 Miltenyi Biomedicine GmbH · Milwaukee, Wisconsin · NCT06708845

• Targeted CAR-T therapy for autoimmune diseases

  This study is testing a new type of CAR-T therapy to see if it can help people with active autoimmune diseases feel better and manage their symptoms.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Bengbu, Anhui · NCT06548607

• Combination treatment for autoimmune disorders using specialized cells and chemotherapy

  This study is testing a new combination of specialized cells and chemotherapy to see if it can help people with autoimmune disorders like systemic sclerosis and lupus feel better.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas and 1 other locations · NCT06434363

• Collection of samples from patients with rheumatic diseases

  This study is collecting samples from people with rheumatic diseases to help researchers learn more about these conditions and improve treatments in the future.

  Recruiting Meir Medical Center · Kfar Saba · NCT03473912

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups

  This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07823101

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.